Eli Lilly has received regulatory approval in China for mirikizumab, a drug used to treat moderately-to-severely active Crohn’s disease and ulcerative colitis, expanding access to the digestive immunity treatment in the world’s second-largest pharmaceutical market.
The approval marks Lilly China’s first clearance for an innovative medicine in the digestive immunity category.
Mirikizumab is already authorised for treatment in multiple other countries, including the United States, and forms part of Lilly’s broader portfolio of medicines in China that address conditions such as Alzheimer’s disease, diabetes, and obesity. Details regarding the launch timeline or pricing for the Chinese market have not been disclosed.
The approval strengthens China’s treatment options for patients with chronic inflammatory bowel disease and highlights the growing focus on innovative therapies in the region’s healthcare sector.
